Natural killer cells in intracranial neoplasms: Presence and therapeutic efficacy against brain tumours

Journal of Neuro-Oncology

Volumn 116, Issue 1, 2014, Pages 1-9

  Kmiecik, Justyna ^a   Zimmer, Jacques ^b   Chekenya, Martha ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Brain tumour; Immunotherapy; NK cells; Prognosis; Tumour infiltrating lymphocytes

Indexed keywords

ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; REVIEW;

BRAIN NEOPLASMS; HUMANS; KILLER CELLS, NATURAL;

EID: 84891750270     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1265-5     Document Type: Review

References (62)

1. Ali-Osman F (ed) (2005) Brain tumors. Humana Press, New Jersey
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2005-2009. Neuro-oncology 14(Suppl 5):v1-v49
3. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France
4. Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7:12
5. Yang I, Han SJ, Kaur G, Crane C, Parsa AT (2010) The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 17:6-10
6. Sonabend AM, Rolle CE, Lesniak MS (2008) The role of regulatory T cells in malignant glioma. Anticancer Res 28:1143-1150
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? the example of natural killer cells. Science 331:44-49
8. Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumour immunotherapy with therapeutic antibodies. Front Immunol 4:76
9. Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495-502
10. Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306:1517-1519
11. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG (1998) Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 187:813-818
12. Purdy AK, Campbell KS (2009) Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 8:2211-2220
13. Thielens A, Vivier E, Romagne F (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 24:239-245
14. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223
15. Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M (2000) Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7-17
16. Topham NJ, Hewitt EW (2009) Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 128:7-15
17. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430
18. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932-5943
19. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861
20. Hsia JY, Chen JT, Chen CY, Hsu CP, Miaw J, Huang YS, Yang CY (2005) Prognostic significance of intratumoural natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J 28:335-340
21. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88:577-583
22. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M (2003) Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20:445-451
23. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH (2007) Groupe d'etude des lymphomes de la: peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 18:1209-1215
24. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L (2002) Prognostic significance of tumour infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23-28
25. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530-3539
26. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V (2012) Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 22:159-174
27. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596-7603
28. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B (2010) Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 16:3399-3408
29. Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M (2013) Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 4(9):1507-1526
30. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861-1871
31. Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA (2012) NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 18:1827-1834
32. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS (2011) Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 34:382-389
33. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumours. J Neuroimmunol 100:216-232
34. Parney I (2012) Basic concepts in glioma immunology. In: Yamanaka R (ed) Glioma. Springer, New York, pp 42-52
35. Servadei F, Parente R, Bucci M, Beltrandi E, Tognetti F, Gaist G (1983) Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients. J Neurooncol 1:327-332
36. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology 12:7-13
37. Dietrich J, Rao K, Pastorino S, Kesari S (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 4:233-242
38. Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-oncology 13:393-400
39. Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61:738-743
40. Vaquero J, Coca S, Escandon J, Magallon R, Martinez R (1990) Immunohistochemical study of IOT-10 natural killer cells in brain metastases. Acta Neurochir 104:17-20
41. Vaquero J, Zurita M, Coca S (2012) Clinical behavior in metastatic brain disease is not influenced by the immunological defense mediated by CD57 NK-cells. Int J Surg Oncol 2012:834852
42. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116:3865-3874
43. Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT (2011) Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 115:505-511
44. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148-1152
45. Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J, Chekenya M (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. doi: 10.1016/j.jneuroim.2013.08.013
46. Rossi ML, Esiri MM, Jones NR, Coakham HB, Moss TH, Cruz-Sanchez FF, Carey MP (1991) Characterization of the mononuclear cell infiltrate and HLA-Dr expression in 19 oligodendrogliomas. Surg Neurol 36:119-125
47. Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, Maillo A, Barcena P, Garcia-Macias MC, Lopes MC, de Oliveira C, Orfao A, Tabernero MD (2012) Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 181:1749-1761
48. Chiu TL, Lin SZ, Hsieh WH, Peng CW (2009) AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int J Oncol 35:1361-1367
49. Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, Nava S, Anghileri E, Cuppini L, Cuccarini V, Ciusani E, Dossena M, Pollo B, Mantegazza R, Parati EA, Finocchiaro G (2013) The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2:e23401
50. Zhang Z, Su T, He L, Wang H, Ji G, Liu X, Zhang Y, Dong G (2012) Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma. Tohoku J Exp Med 226:59-68
51. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12:24
52. Vauleon E, Avril T, Collet B, Mosser J, Quillien V (2010) Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010:2010. doi: 10.1155/2010/689171. Epub 2010 Oct 4
53. Ishikawa E, Takano S, Ohno T, Tsuboi K (2012) Adoptive cell transfer therapy for malignant gliomas. Adv Exp Med Biol 746:109-120
54. Sankhla SK, Nadkarni JS, Bhagwati SN (1996) Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 27:133-140
55. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175-182
56. Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A (2011) Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 10:1036-1045
57. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS (2012) A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120:4324-4333
58. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L (2013) Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 4:15
59. Bignon JD, Gagne K (2005) KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 17:553-559
60. Poli A KJ, Domingues O, Hentges F, Blery M, Chekenya M, Boucraut J, Zimmer J (2013) Natural killer cells in central nervous system disorders. J Immunol 190(11):5355-5362. doi: 10.4049/jimmunol.1203401
61. Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, Shearer GM (1999) Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882-4892
62. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10:133-146